menu
    • menu
    [{"orgOrder":0,"company":"Eidos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Acoramidis Hydrochloride","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Eidos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eidos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eidos Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Eidos Therapeutics","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2020","type":"Merger","leadProduct":"Acoramidis Hydrochloride","moa":"Transthyretin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Eidos Therapeutics","amount2":2.8300000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":2.8300000000000001,"dosageForm":"Oral","sponsorNew":"Eidos Therapeutics \/ Bridgebio Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Eidos Therapeutics \/ Bridgebio Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Eidos Therapeutics

    Menu

    Eidos Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Eidos Therapeutics

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Eidos Therapeutics

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Acoramidis Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : BridgeBio Pharma

                            Deal Size : $2,830.0 million

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Bridgebio Pharma and Eidos Therapeutics Announce Merger Agreement

                            Details : Using this platform Eidos will be able to capitalize on BridgeBio’s global clinical development and regulatory expertise, its developing commercial infrastructure, and its broader capital base to reach more patients more effectively.

                            Brand Name : AG10

                            Molecule Type : Small molecule

                            Upfront Cash : $175.0 million

                            October 05, 2020

                            Lead Product(s) : Acoramidis Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : BridgeBio Pharma

                            Deal Size : $2,830.0 million

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Eidos Therapeutics

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Eidos Therapeutics

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Acoramidis Hydrochloride

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Eidos Therapeutics Appoints Industry Leaders With Significant Development and Commercial Expertise to Board of...

                            Details : Eidos is developing acoramidis (formerly AG10) as a potentially best-in-class treatment option for ATTR patients.

                            Brand Name : AG10

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 07, 2020

                            Lead Product(s) : Acoramidis Hydrochloride

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth